In Brief: Expanded Access to Mifepristone
The Medical Letter on Drugs and Therapeutics · 2023
DOI: 10.58347/tml.2023.1670c ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: Abortion, Induced, Misoprostol, Abortifacient Agents, Nonsteroidal, Abortifacient Agents, Steroidal.
Abstract (Originalsprache)
First approved in 2000 for termination of pregnancies of ≤49 days' gestation, the indication for the oral antiprogestin mifepristone (Mifeprex, and generics) was expanded in 2016 to include pregnancies of up to 10 weeks' gestation. A single 200-mg oral dose of mifepristone followed 24-48 hours later by a single 800-mcg buccal dose of the prostaglandin analog misoprostol terminates early intrauterine pregnancies in about 95% of women.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Zitieren
APA
(2023). In Brief: Expanded Access to Mifepristone. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1670c
Vancouver
In Brief: Expanded Access to Mifepristone. The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1670c
BibTeX
@article{euvimed2023,
title = {In Brief: Expanded Access to Mifepristone},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2023},
doi = {10.58347/tml.2023.1670c}
}
EUVIMED